EVALUATION OF THE PROGNOSTIC EPIDEMIOLOGICAL AND ECONOMIC EFFICACY OF VACCINATION AGAINST PNEUMOCOCCAL INFECTION IN MEN OF WORKING AGE WITH VARIOUS CHRONIC DISEASES

Abstract

Aim. The study of the prognosis of epidemiological and economic effects of pneumococcal vaccination in laboring males with various chronic diseases. Materials and methods. Within the predictive (Markov) model, based on the published data, assessment of 5-year horizon pneumo­ coccal vaccination of laboring males perceived effectiveness in reducing mortality, avoiding mor­ bidity and economic loss in the country had been processed. According to the official statistics in laboring are within the risk group for pneumonia. Data source for the cost of the healthcare for disease had been the compulsory health insurance system 2016 state tariffs, for the vaccination cost results of the PCV13 procurement bidding had been used. Results. Data extrapolation from national and international studies to the cohort of individuals with chronic respiratory diseases, cardiovascular diseases and diabetes mellitus vaccinated against pneumococcal infection showed a significant decrease in the risk of un­ derlying diseases complications (OP=0,58, p<0,05), hospitalizations number (OP=0,02, p<0,05) and expected mortality. The cost of vaccination in the evaluated group of patients was 25 869.5 min RUB. According to the modeling results PCV13 use will allow to statistically significantly decrease the number of relapses and hospitalizations that will permit to save up to 14 359.9 min rubles annually. Thus, in the two-year horizon, the total fiscal savings will amount to 2 850.30 million RUB and at least 61 702 of the patients' lives retained in a 5-year term with a single dose PCV13 administration. Conclusion. The study results indicate potential high epidemiological and clinical effectiveness of pneumococcal vaccination of the laboring males suffering from chronic diseases. Vaccination as a cost-effective investment in healthcare creates the opportunity of reduc­ tions in morbidity, number of exacerbations, hospitalization rate and mortality in the vaccinated cohort.